274
Participants
Start Date
May 12, 2021
Primary Completion Date
January 15, 2026
Study Completion Date
January 15, 2026
Osimertinib
Single arm treated by osimertinib
Research Site, Abbeville
Research Site, Aix-en-Provence
Research Site, Angers
Research Site, Antibes
Research Site, Avignon
Research Site, Bastia
Research Site, Bayonne
Research Site, Bordeaux
Research Site, Bourg-en-Bresse
Research Site, Brest
Research Site, Cannes
Research Site, Chambéry
Research Site, Chauny
Research Site, Cholet
Research Site, Clermont-Ferrand
Research Site, Colmar
Research Site, Contamine-sur-Arve
Research Site, Créteil
Research Site, Elbeuf
Research Site, Epagny METZ Tessy
Research Site, Évreux
Research Site, La Roche-sur-Yon
Research Site, Libourne
Research Site, Limoges
Research Site, Lyon
Research Site, Marseille
Research Site, Meaux
Research Site, Mulhouse
Research Site, Orléans
Research Site, Paris
Research Site, Poitiers
Research Site, Quimper
Research Site, Reims
Research Site, Rouen
Research Site, Saint-Denis
Research Site, Saint-Grégoire
Research Site, Saint-Pierre
Research Site, Saint-Priest-en-Jarez
Research Site, Saint-Quentin
Research Site, Toulon
Research Site, Toulouse
Research Site, Valenciennes
Research Site, Vannes
Research Site, Villefranche-sur-Saône
Research Site, Villenave-dornon
Research Site, Villeurbanne
Lead Sponsor
AstraZeneca
INDUSTRY